10 results about "Cd4 cell" patented technology

HIV-1-related immune activation is not only associated with AIDS progression, but also with CD4+ after cART treatment. + Insufficient T cell recovery is a contributing factor. This invention focuses on nicotinamide adenine dinucleotide (NAD) precursors and their potential in modulating host immune cells against HIV-1. Treatment with nicotinamide mononucleotide (NMN) inhibits HIV-1 infection at the post-transcriptional stage by targeting ACH-2 and primary CD4 cells. + Viral production in T cells. On one hand, the NMN treatment preferentially reduces CD25. + CD4 + Intracellular HIV-1 p24 production in T cells. On the other hand, using in vitro, ex vivo, and in vivo models, NMN consistently inhibited the expression of late T cell activation markers, including CD25 and HLA-DR. Furthermore, NMN works by assisting the production of CD4+. + T-cell regeneration to improve the therapeutic efficacy of cART in HIV-1-infected humanized mice.

HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and / or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and / or broadly neutralizing antibodies are administered.

The present invention relates to the field of biomedicine technology, and in particular to the use of POSTN protein in the preparation of diagnostic and therapeutic products for Treg cell disorder diseases, which include one or more diseases of tumors, autoimmune diseases, chronic infections and chronic inflammation. Cell experiments have shown that POSTN protein can regulate the differentiation of initial CD4 cells into Treg cells, and the results of bioinformatics analysis show that POSTN protein is highly expressed in the tumor microenvironment. The above results suggest that the secretion of Treg cells can be stimulated by POSTN protein, or a pharmaceutical preparation can be prepared using POSTN protein in the tumor microenvironment as an identification target, or a diagnostic product can be prepared using POSTN protein biomarkers in the tumor microenvironment. POSTN protein is expected to be used in the preparation of diagnostic and therapeutic products for Treg cell disorder diseases.

The invention provides a CD4 + T monoclonal cell culture medium, a culture method and application of the CD4 + T monoclonal cell culture medium. The culture medium comprises N-acetylcysteine and Trolox. According to the invention, the long-standing technical problem that natural CD4 + T cells are difficult to directly and stably form a monoclonal line is successfully solved. Through a density gradient dilution method and a culture medium formula, the formation of a monoclonal cell line with uniform and stable genetic background by efficient amplification starting from a single CD4 + T cell is realized for the first time. The CD4 + T cell is high in monoclonal formation efficiency and good in monoclonal growth state, and the preparation efficiency of the gene editing cell strain is greatly improved. According to the invention, a cell line with hCCR5-delta 32 CD4 + T cell point mutation is successfully constructed by using a monoclonal cell culture method, and important scientific research reference data is provided for treatment of diseases related to the CCR5 gene.

The present disclosure provides CD4 T cell clones from at least two different T cell donors. + Polydonor CD4 generated by genetically modifying T cells IL-10 In addition, polydonor CD4 IL-10 Methods for generating polydonor CD4 cells and for immune tolerance IL-10 Methods of using the cells, methods of treating GvHD, cell and organ transplantation, cancer, autoimmune and inflammatory diseases, and other immune disorders are provided.

The invention pertains to an inducible CRISPR system for controlling expression of a CRISPR complex with an inducible fusion promoter. One embodiment of the invention provides HIV LTR-minimal Drosophila hsp70 fusion promoter that can be used for inducible co-expression of gRNA and Cas9 in HIV-infected cells to target cellular cofactors such as Cyclin T1. A single introduction of such embodiment leads to sustained suppression of HIV replication in stringent, chronically infected HeLa-CD4 cell lines as well as in T-cell lines. In another embodiment, the invention further relates to enhancement of HIV suppression by incorporating cis-acting ribozymes immediately upstream of the gRNA in the inducible CRISPR system construct. The inducible fusion promoter is adaptable for other tissue- or cell-type specific expression of the inducible CRISPR system.

The invention belongs to the field of medical research, and particularly relates to a method, system and device for evaluating HIV antiviral therapy compliance and a storage medium. The method comprises the following steps: acquiring index data for reflecting ART compliance of an HIV infected person, wherein the index data comprises a nursing retention state, a drug holding rate and a CD4 cell count; constructing a group trajectory model GBTM, and identifying trajectory subgroups of different antiviral treatment compliance in the HIV infected person based on the index data; utilizing a Logistic regression model to evaluate the influence of the demology and ART variable level of different HIV infected persons on the affiliation probability of each trajectory subgroup; utilizing a Cox proportional risk model to evaluate the association between each track subgroup and all-factor death, AIDS death and non-AIDS death; and finally, constructing a dynamic prediction model based on the nursing retention, the drug coverage rate and the CD4 cell counting data by using the combined model, so as to realize real-time early warning of the death risk.

HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and / or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and / or broadly neutralizing antibodies are administered.

The invention belongs to the technical field of biological medicines, and particularly relates to application of TNFR2 in preparation of a medicine for treating HIV infection. It is found for the first time that TNFR2 protein can inhibit infection of HIV pseudoviruses on CD4 cells by blocking combination of HIV envelope protein gp120 and CD4. Compared with the prior art, the invention has the following advantages: 1, experimental evidence is provided for the combination of TNFR2 and gp120 for the first time; 2, the binding site of the TNFR2 on the gp120 is close to that of the CD4, and the binding of the gp120 and the CD4 cell can be blocked; and 3, it is proved for the first time that the TNFR2 protein can inhibit infection of HIV pseudovirus on cells. The invention has important theoretical and practical meanings for researching the inhibition of the TNFR2 protein on HIV (Human Immunodeficiency Virus) infection.

The invention relates to the technical field of biological medicine, in particular to application of POSTN protein in preparation of a Treg cell dysregulated disease diagnosis and treatment product, and Treg cell dysregulated diseases comprise one or more diseases of tumors, autoimmune diseases, chronic infection and chronic inflammation. Cell experiments prove that the POSTN protein can regulate and control initial CD4 cells to be differentiated into Treg cells, and bioinformatics analysis results show that the POSTN protein in a tumor microenvironment is highly expressed. The result prompts that secretion increase of the Treg cells can be stimulated through the POSTN protein, or the POSTN protein in a tumor microenvironment is used as a recognition target to prepare a pharmaceutical preparation, or a POSTN protein biomarker in a tumor position environment is used to prepare a diagnostic product, and the POSTN protein is expected to be applied to preparation of a Treg cell dysregulated disease diagnosis and treatment product.